Alterity Therapeutics Limited is a biotechnology company engaged in the discovery and development of therapeutic candidates for neurodegenerative disorders. The company focuses on diseases such as Parkinson's disease multiple system atrophy and related conditions. Its lead candidate ATH434 is designed to modulate iron homeostasis and reduce protein aggregation in the brain. Alterity Therapeutics Limited was incorporated in Australia and maintains its principal executive office in Melbourne.

Alterity Therapeutics Limited generates revenue primarily through licensing agreements and research collaborations. The company has entered into a sublicensing arrangement for its PBT2 asset with Professor Colin Masters which may yield future royalty income. It also holds a license from UniQuest for zinc ionophore technology aimed at addressing antimicrobial resistance. Additionally the company receives grant funding from organizations such as the Michael J Fox Foundation to support its preclinical and clinical programs.

Alterity Therapeutics Limited occupies a niche position in the biotechnology sector as a developer of disease modifying therapies for rare neurodegenerative diseases where approved treatments are lacking. The company’s lead program ATH434 has received orphan drug designation from both the US FDA and the European Commission and has been granted fast track status by the FDA for multiple system atrophy. Key competitors working on similar indications include Lundbeck with Lu AF82422 Takeda in partnership with AstraZeneca with TAK 341 MEDI341 Ono Pharmaceuticals with Ono 2808 Teva Pharmaceuticals with TEV 56286 Yoda Therapeutics with YA 101 and AskBio with AAV GDNF. Alterity Therapeutics Limited differentiates itself through its iron centric mechanism of action its strong intellectual property portfolio and its focus on targets that have not yet been successfully addressed by other firms.

Alterity Therapeutics Limited works with a range of collaborators that include academic institutions contract research organizations and funding bodies. Specific partners mentioned in its filings are Vanderbilt University Medical Center which collaborates on the natural history study for multiple system atrophy the Michael J Fox Foundation which provides grant support for Parkinson’s disease research Professor Colin Masters to whom the company has sublicensed its PBT2 asset and UniQuest the commercialisation arm of the University of Queensland which licenses zinc ionophore technology for antimicrobial resistance applications. The company also engages with clinical trial sites and regulatory advisors to advance its product candidates.